Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.44 |
| ▸ | CTSK | P43235 | 13/20 | 0.42 |
| ▸ | CTSS | P25774 | 7/20 | 0.42 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.38 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294857 | 0.90 | CTSL (0.47) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6699096 | 0.89 | CTSL (0.45) | CTSLCTSKCTSSCTSBTAS1R3 | |
| SCHEMBL6701483 | 0.87 | CTSK (0.54) | CTSLCTSKCTSSCTSBTAOK1 | |
| SCHEMBL6992575 | 0.87 | USP30 (0.48) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6294856 | 0.86 | KLKB1 (0.43) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6699225 | 0.86 | CTSK (0.53) | CTSLCTSKCTSSCTSBTAOK1 | |
| SCHEMBL6699086 | 0.85 | KLKB1 (0.43) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6698003 | 0.84 | CTSL (0.45) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6701575 | 0.84 | TRPV1 (0.44) | CTSL | |
| SCHEMBL6295797 | 0.84 | KLKB1 (0.43) | CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LIMITED (GB) | 2004-06-03 | — | — | US | disclosed |
| EP-1358176-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | Amura Therapeutics Limited (GB) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002057246-A2 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106805-A1 | Inhibitors of cruzipain and other cysteine proteases | CTRL, CPN1, CPA1 | CTSL 15/4885CTSK 46/4885CTSS 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.